Tivozanib As Maintenance Therapy In GYN
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01972516|
Recruitment Status : Terminated (due to slow accrual)
First Posted : October 30, 2013
Results First Posted : August 24, 2016
Last Update Posted : June 5, 2017
Dana-Farber Cancer Institute
National Comprehensive Cancer Network
AVEO Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Susana M. Campos, MD, Dana-Farber Cancer Institute
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Terminated early due to low accrual.